KalVista Pharmaceuticals, Inc. - Common Stock (NQ:KALV)

27.00 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jun 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about KalVista Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results

July 07, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 05, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Presents New Data for Sebetralstat and its Oral Factor XIIa Inhibitor Program

July 05, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present Data at the 2022 Meeting of the European Academy of Allergy and Clinical Immunology (EAACI)

June 23, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Presents Promising Preclinical Data for Oral Factor XIIa Inhibitor Program

June 08, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 03, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present at 13th Annual Jefferies Healthcare Conference

June 01, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Announces Changes to Board of Directors

May 27, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Announces Non-Proprietary Name Selection for KVD900

May 17, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present at 21st Annual Needham Virtual Healthcare Conference

April 11, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 04, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Announces Publication of Additional KVD900 Data in Clinical & Experimental Allergy

March 22, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals: Q3 Earnings Insights ↗

March 10, 2022

KalVista Pharmaceuticals (NASDAQ:KALV) reported its Q3 earnings results on Thursday, March 10, 2022 at 07:00 AM. Here's what investors need to know about the...

Via Benzinga

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗

February 27, 2022

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the...

Via Talk Markets

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗

February 27, 2022

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...

Via Benzinga

KalVista Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference

February 03, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present Data on Oral On-Demand HAE Therapy KVD900 at AAAAI 2022

February 02, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 02, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Announces Publication of Oral HAE Therapy KVD900 Phase 1 Data in Journal of Allergy and Clinical Immunology

January 24, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 04, 2022

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals: Q2 Earnings Insights ↗

December 09, 2021

KalVista Pharmaceuticals (NASDAQ:KALV) reported its Q2 earnings results on Thursday, December 9, 2021 at 06:30 AM. Here's what investors need to know about the...

Via Benzinga

KalVista Pharmaceuticals Reports Second Fiscal Quarter Results

December 09, 2021

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 03, 2021

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Provides Progress Update on KVD900 for Oral On-Demand Treatment of Hereditary Angioedema

November 10, 2021

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

November 09, 2021

From KalVista Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance ↗

November 10, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:...

Via Benzinga

KalVista Pharmaceuticals Presents Data Demonstrating KVD900 Achieves Rapid Exposure and Improves Outcomes as Oral On-Demand Treatment of HAE

November 08, 2021

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 04, 2021

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 04, 2021

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present at Cantor Virtual Global Healthcare Conference

September 21, 2021

From KalVista Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.